Journal
FRONTIERS IN CARDIOVASCULAR MEDICINE
Volume 9, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fcvm.2022.900381
Keywords
short-chain fatty acids; CVD; inflammation; glucolipid metabolism; blood pressure; gut-brain axis
Categories
Funding
- National Natural Science Foundation of China
- [81273945]
Ask authors/readers for more resources
SCFAs play a key role in maintaining intestinal integrity, anti-inflammation, modulating glucolipid metabolism, blood pressure, and activating the gut-brain axis, with recent advances suggesting a promising way to prevent and treat CVDs through controlling SCFAs.
Cardiovascular diseases (CVDs) have been on the rise around the globe in the past few decades despite the existing guidelines for prevention and treatment. Short-chain fatty acids (SCFAs) are the main metabolites of certain colonic anaerobic bacterial fermentation in the gastrointestinal tract and have been found to be the key metabolites in the host of CVDs. Accumulating evidence suggest that the end-products of SCFAs (including acetate, propionate, and butyrate) interact with CVDs through maintaining intestinal integrity, anti-inflammation, modulating glucolipid metabolism, blood pressure, and activating gut-brain axis. Recent advances suggest a promising way to prevent and treat CVDs by controlling SCFAs. Hence, this review tends to summarize the functional roles carried out by SCFAs that are reported in CVDs studies. This review also highlights several novel therapeutic interventions for SCFAs to prevent and treat CVDs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available